Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by InnoCare Pharma

< Previous 1 2 Next >
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China
From InnoCare Pharma
Via GlobeNewswire
InnoCare Releases 2025 Interim Results and Business Highlights
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
From InnoCare Pharma
Via Business Wire
Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress
From InnoCare Pharma
Via Business Wire
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China
From InnoCare Pharma
Via Business Wire
InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA
From InnoCare Pharma
Via Business Wire
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2024 Results and Business Highlights
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China
From InnoCare Pharma
Via Business Wire
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
From InnoCare Pharma
Via Business Wire
Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
From InnoCare Pharma
Via Business Wire
InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2024 Interim Results and Business Highlights
From InnoCare Pharma
Via Business Wire
British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
From InnoCare Pharma
Via Business Wire
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress
From InnoCare Pharma
Via Business Wire
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
From InnoCare Pharma
Via Business Wire
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
From InnoCare Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.